Enhabit Files Definitive Proxy Materials

TL;DR

Enhabit filed proxy docs, no fee needed. Standard procedure.

AI Summary

Enhabit, Inc. filed a DEFA14A, indicating it is providing definitive additional materials to the SEC. This filing relates to their proxy statement and confirms no fee was required for this submission. The company, formerly known as Encompass Health Home Health Holdings, Inc. until February 18, 2020, is headquartered in Dallas, Texas.

Why It Matters

This filing is a standard procedural step for public companies to provide updated or additional information related to shareholder meetings and voting, ensuring transparency and compliance.

Risk Assessment

Risk Level: low — This is a routine SEC filing for proxy materials and does not contain new financial information or strategic decisions that would inherently increase risk.

Key Players & Entities

• Enhabit, Inc. (company) — Registrant
• Encompass Health Home Health Holdings, Inc. (company) — Former company name
• 20200218 (date) — Date of name change
• 6688 N. CENTRAL EXPRESSWAY, SUITE 1300 (address) — Business and mailing address
• DALLAS (location) — City
• TX (location) — State
• 75206 (postal_code) — ZIP code
• 4696216419 (phone_number) — Business phone

FAQ

Key Financial Figures

• $136 — e revenue per visit, from approximately $136 in FY 2022, to approximately $140 in FY
• $140 — ately $136 in FY 2022, to approximately $140 in FY 2023, to approximately $145 in th
• $145 — ately $140 in FY 2023, to approximately $145 in the first quarter of 2024. These imp
• $250,000 — an initial investment of approximately $250,000 to $350,000, allowing Enhabit to capita
• $350,000 — investment of approximately $250,000 to $350,000, allowing Enhabit to capitalize on grow

Filing Documents

• d849970ddefa14a.htm (DEFA14A) — 66KB
• g849970g08g08.jpg (GRAPHIC) — 29KB
• 0001193125-24-157912.txt ( ) — 108KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under Rule 14a-12 Enhabit, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Enhabit Details Decisive Actions to Successfully Stabilize Business and Position Company for Value Creation Files Definitive Proxy Materials and Mails Letter to Stockholders AREXs Unqualified Slate of Nominees Risks Detracting from the Talent Currently on the Board Urges Stockholders to Vote FOR Only Enhabits Nine Nominees on the YELLOW Proxy Card DALLAS, June 10, 2024 Enhabit, Inc. (NYSE: EHAB) (Enhabit or the Company), a leading home health and hospice provider, today announced that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with its upcoming 2024 annual meeting of stockholders (the 2024 Annual Meeting) scheduled for July 25, 2024. Stockholders of record as of the close of business on June 5, 2024, are entitled to vote at the 2024 Annual Meeting. In connection with the filing of its definitive proxy statement, Enhabit is mailing a letter to stockholders. Enhabits definitive proxy materials and other materials regarding the Board of Directors recommendation for the 2024 Annual Meeting can be found at investors.ehab.com. The full text of the letter follows: PROTECT THE VALUE OF YOUR INVESTMENT: VOTE THE ENCLOSED YELLOW PROXY CARD FOR ENHABITS HIGHLY QUALIFIED AND COMMITTED DIRECTOR NOMINEES Dear Fellow Stockholder, At our upcoming 2024 Annual Meeting of Stockholders (Annual Meeting), you will have an important decision to make about the future of Enhabit Home Health & Hospice (Enhabit or the Company) whether our Board should be replaced and control of Enhabit handed to one of our stockholders, AREX Capital Management, LP (together with its affiliates, AREX). Your current Board unanimously believes the answer to this question is emphatically, no. Allow us to explain. Previously a subsidiary of Encompass Health Corporation (Encompass), Enhabit has been a public company for just seven full quarters. Neither our financial results nor our stock performance has satisfied expectations during this period and certainly have not met the standard your Board has set for Enhabit. This is due to a variety of factors, including the structure and condition of our Company at the time of the spin-off, as well as industry headwinds that were exacerbated due to our business mix. We also experienced a few operational missteps, which did not meet the high standards we have set for ourselves. But that is the past. Looking forward, the Company is focused on improving our execution in areas that we directly control beyond business mix and market conditions. As demonstrated by our financial performance at the end of 2023 and beginning of 2024, the Board and management team have taken the necessary steps to evolve Enhabit into a stronger, more resilient post-spin public company, well-positioned for growth, including: Standing up a public company despite challenging structural circumstances, including enhancing our standalone financial control environment; Executing a well-designed Board refreshment program that included the appointment of two new directors pursuant to an agreement with stockholders; Undertaking a comprehensive nine-month review process to evaluate all strategic alternatives for the Company, including a potential sale; and Most importantly, executing on its strategic plan to stabilize the business amidst significant industry headwinds. Despite our demonstrable progress and current trajectory, AREX has initiated a proxy contest to replace the majority of the Board with a seven-candidate slate that has largely outdated experience and numerous other flaws. Most prominently, none of the six independent candidates have any board experience at a NYSE or NASDAQ-listed company. Furthermore, if AREX takes control of the Company, their stated intent is to institute a Transformation Committee, which will presumably operate as a shadow management team, to implement a yet-to-be-disclosed strategic plan this is not the recipe for success. We have engaged with AREX extensively since our infancy as a public com